Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04739202 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)(IMMUNOGAST) | completed | Phase 2 | 54 | Hospices Civils de LyonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05177211 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | completed | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 9, 2026 |
| clinicaltrials |
| NCT05730712 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06513364 | Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | completed | Phase 2 | 40 | Beijing Wehand-Bio Pharmaceutical Co., LtdINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT00304278 | Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) | completed | Phase 2 | 21 | Southern Illinois UniversityOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03494179 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 106 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 127 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01702831 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance(BuMelMCRN001) | completed | Phase 2 | 78 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03949153 | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis(CRIRIN) | completed | Phase 1 / Phase 2 | 19 | University Hospital, Strasbourg, FranceOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04188405 | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04258033 | A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)(KUNPENG) | completed | Phase 2 | 145 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04632459 | Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04848974 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma(ADDICT-pedGLIO) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05379972 | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | completed | Phase 2 | 9 | University of Colorado, DenverOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | completed | Phase 1 / Phase 2 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT00238628 | A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Stanford UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | completed | Phase 1 / Phase 2 | 336 | Constellation PharmaceuticalsINDUSTRY | 9 | Jun 4, 2026 | clinicaltrials |
| NCT02286726 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00534430 | Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT01009177 | Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) | completed | Phase 2 | 80 | ActelionINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03196830 | CAR-T for R/R B-NHL | completed | Phase 2 | 168 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT03786783 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Jun 2, 2026 | clinicaltrials |
| NCT04539444 | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma | completed | Phase 2 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04954339 | DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab(DYNAMIC) | completed | Phase 2 | 40 | Tae Won KimOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05322330 | Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619937 | Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 31 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04847466 | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05542342 | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.(SITISVEAL) | completed | Phase 2 | 16 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05664178 | Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06434909 | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | completed | Phase 2 | 9 | Indiana UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 131 | NewLink Genetics CorporationINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT02583893 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02645149 | Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma(Match Mel) | completed | Phase 2 | 216 | Melanoma Institute AustraliaOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT00159484 | Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 14 | May 28, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT00932412 | The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)(CLARA) | completed | Phase 2 | 735 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03433183 | SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | completed | Phase 2 | 21 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2026source: clinicaltrials